Kerem Ozturk1, Esra Soylu1, Zuzan Cayci2. 1. Department of Radiology, University of Minnesota Health, B-226 Mayo Memorial Building, MMC 292, 420 Delaware Street S.E., Minneapolis, MN, 55455, USA. 2. Department of Radiology, University of Minnesota Health, B-226 Mayo Memorial Building, MMC 292, 420 Delaware Street S.E., Minneapolis, MN, 55455, USA. cayci001@umn.edu.
Abstract
PURPOSE: To determine if dynamic susceptibility contrast perfusion MR imaging (DSC-pMRI) can predict significant genomic alterations in glioblastoma (GB). METHODS: A total of 47 patients with treatment-naive GB (M/F: 23/24, mean age: 54 years, age range: 20-90 years) having DSC-pMRI with leakage correction and genomic analysis were reviewed. Mean relative cerebral blood volume (rCBV), maximum rCBV, relative percent signal recovery (rPSR), and relative peak height (rPH) were derived from T2* signal intensity-time curves by ROI analysis. Major genomic alterations of IDH1-132H, MGMT, p53, EGFR, ATRX, and PTEN status were correlated with DSC-pMRI-derived GB parameters. Statistical analysis was performed utilizing the independent-samples t-test, ROC (receiver operating characteristic) curve analysis, and multivariable stepwise regression model. RESULTS: rCBVmean and rCBVmax were significantly different in relation to the IDH1, MGMT, p53, and PTEN mutation status (all p < 0.05). The rPH of the p53 mutation-positive GBs (mean 5.8 ± 2.8) was significantly higher than those of the p53 mutation-negative GBs (mean 4.0 ± 1.5) (p = 0.022). Multivariable stepwise regression analysis revealed that the presence of IDH-1 mutation (B = - 2.81, p = 0.005) was associated with decreased rCBVmean; PTEN mutation (B = - 1.21, p = 0.003) and MGMT methylation (B = - 1.47, p = 0.038) were associated with decreased rCBVmax; and ATRX loss (B = - 1.05, p = 0.008) was associated with decreased rPH. CONCLUSION: Significant associations were identified between DSC-pMRI-derived parameters and major genomic alterations, including IDH-1 mutation, MGMT methylation, ATRX loss, and PTEN mutation status in GB.
PURPOSE: To determine if dynamic susceptibility contrast perfusion MR imaging (DSC-pMRI) can predict significant genomic alterations in glioblastoma (GB). METHODS: A total of 47 patients with treatment-naive GB (M/F: 23/24, mean age: 54 years, age range: 20-90 years) having DSC-pMRI with leakage correction and genomic analysis were reviewed. Mean relative cerebral blood volume (rCBV), maximum rCBV, relative percent signal recovery (rPSR), and relative peak height (rPH) were derived from T2* signal intensity-time curves by ROI analysis. Major genomic alterations of IDH1-132H, MGMT, p53, EGFR, ATRX, and PTEN status were correlated with DSC-pMRI-derived GB parameters. Statistical analysis was performed utilizing the independent-samples t-test, ROC (receiver operating characteristic) curve analysis, and multivariable stepwise regression model. RESULTS: rCBVmean and rCBVmax were significantly different in relation to the IDH1, MGMT, p53, and PTEN mutation status (all p < 0.05). The rPH of the p53 mutation-positive GBs (mean 5.8 ± 2.8) was significantly higher than those of the p53 mutation-negative GBs (mean 4.0 ± 1.5) (p = 0.022). Multivariable stepwise regression analysis revealed that the presence of IDH-1 mutation (B = - 2.81, p = 0.005) was associated with decreased rCBVmean; PTEN mutation (B = - 1.21, p = 0.003) and MGMT methylation (B = - 1.47, p = 0.038) were associated with decreased rCBVmax; and ATRX loss (B = - 1.05, p = 0.008) was associated with decreased rPH. CONCLUSION: Significant associations were identified between DSC-pMRI-derived parameters and major genomic alterations, including IDH-1 mutation, MGMT methylation, ATRX loss, and PTEN mutation status in GB.
Authors: P D Chang; H R Malone; S G Bowden; D S Chow; B J A Gill; T H Ung; J Samanamud; Z K Englander; A M Sonabend; S A Sheth; G M McKhann; M B Sisti; L H Schwartz; A Lignelli; J Grinband; J N Bruce; P Canoll Journal: AJNR Am J Neuroradiol Date: 2017-03-02 Impact factor: 3.825
Authors: Ramon F Barajas; J Graeme Hodgson; Jamie S Chang; Scott R Vandenberg; Ru-Fang Yeh; Andrew T Parsa; Michael W McDermott; Mitchel S Berger; William P Dillon; Soonmee Cha Journal: Radiology Date: 2010-02 Impact factor: 11.105
Authors: Hyung Jun Jeon; Doo Sik Kong; Kwon Byong Park; Jung Il Lee; Kwan Park; Jong Hyun Kim; Sung Tae Kim; Do Hun Lim; Won Seok Kim; Do-Hyun Nam Journal: Clin Neurol Neurosurg Date: 2009-07-28 Impact factor: 1.876
Authors: Sen Peng; Harshil Dhruv; Brock Armstrong; Bodour Salhia; Christophe Legendre; Jeffrey Kiefer; Julianna Parks; Selene Virk; Andrew E Sloan; Quinn T Ostrom; Jill S Barnholtz-Sloan; Nhan L Tran; Michael E Berens Journal: Neuro Oncol Date: 2017-06-01 Impact factor: 12.300
Authors: Jérémie F Cohen; Daniël A Korevaar; Douglas G Altman; David E Bruns; Constantine A Gatsonis; Lotty Hooft; Les Irwig; Deborah Levine; Johannes B Reitsma; Henrica C W de Vet; Patrick M M Bossuyt Journal: BMJ Open Date: 2016-11-14 Impact factor: 2.692
Authors: Vittorio Stumpo; Lelio Guida; Jacopo Bellomo; Christiaan Hendrik Bas Van Niftrik; Martina Sebök; Moncef Berhouma; Andrea Bink; Michael Weller; Zsolt Kulcsar; Luca Regli; Jorn Fierstra Journal: Cancers (Basel) Date: 2022-03-05 Impact factor: 6.639